Clinical Trial Update: A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Tarceva (erlotinib) as monotherapy in patients with advanced non-small cell lung cancer has completed, with results posted in July 2014…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-07-10